IP Library Granted Patent US 8,911,956
Granted Patent B2
US 8,911,956 · App. 14/183,203 · Granted Dec 16, 2014

Methods of use for an immunoassay detecting fragment Ba

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,911,956
App. No.
14/183,203
Granted
Dec 16, 2014
Kind
B2
Abstract

Methods, compositions and kits for detecting the complement Factor B cleavage product Ba in a biological sample are described. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of or ruling out pre-eclampsia in a pregnant human subject.

Claims (11)

1. A method for ruling out pre-eclampsia in a pregnant human subject, comprising:

contacting a sample of a body fluid obtained at a time period between 8 and 42 weeks of pregnancy from the subject with an antibody to a neo-epitope on the Ba fragment (Ba) of Factor B, said antibody does not substantially recognize Factor B or the Bb fragment (Bb) of Factor B;

detecting whether the antibody binds to the neo-epitope on Ba in the sample; and

identifying as “ruled-out” those pregnant human subjects for which no binding is detected.

2. The method of claim 1 , wherein the sample is obtained at a time period between 10 and 19 weeks of pregnancy.

3. The method of claim 1 , wherein a risk factor of developing pre-eclampsia at a later point in pregnancy or after parturition is assigned.

4. The method of claim 1 , wherein the body fluid is urine.

5. The method of claim 1 , wherein the body fluid is blood.

6. The method of claim 1 , wherein the body fluid is plasma.

7. The method of claim 1 , wherein the body fluid is serum.

8. The method of claim 1 , wherein the neo-epitope on fragment Ba corresponds to residues 26-259 of SEQ ID NO:1 or corresponds to a sequence having at least about 80% sequence identity to residues 26-259 of SEQ ID NO:1.

Assignments (6)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: QUIDEL CORPORATION
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 068657/0827 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →